Fig. 1

Consort flow diagram showing number of subjects screened for study participation and number of participants in each treatment group at baseline, three-, six-, and twelve months of follow-up, with designation of reasons for early discontinuation. The WBV + teriparatide group received whole-body vibration and teriparatide and the teriparatide group received teriparatide alone. WBV whole-body vibration, ITT intention to treat